Jpmorgan Chase & CO Aprea Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

Shares

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 11, 2022	SELL	$0.62 - $1.94 $18,293 - $57,239	-29,505 Reduced 99.99%	4 $0
Q1 2022 May 11, 2022	SELL	$1.59 - $3.16 $262,834 - $522,363	-165,305 Reduced 84.85%	29,509 $55,000
Q4 2021 Feb 10, 2022	BUY	$2.87 - $5.58 $25,344 - $49,276	8,831 Added 4.75%	194,814 $559,000
Q3 2021 Nov 12, 2021	BUY	$3.43 - $5.63 $637,921 - $1.05 Million	185,983 New	185,983 $951,000

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,885
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.